Chardan analyst Geulah Livshits lowered the firm’s price target on Century Therapeutics to $17 from $19 and keeps a Buy rating on the shares post the Q2 report. The company reiterated the timeline for initial human data from its lead CD19 CAR-iNK candidate CNTY-101, which are expected by the end of 2023, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IPSC:
